学院新闻

当前位置:首页  新闻中心  学院新闻

陆鹏举教授讲座通知

时间:2013-07-14来源:机电学院点击:1169

报告题目: Ten-year Development of Para-aortic Blood Pump (PABP) System in

National Cheng Kung University

报告时间: 715日(周一)9:00

报告地点:苏州工业园区星湖街218号生物纳米科技园A4302

报告人: Pong-Jeu Lu (陆鹏举)

Professor of Aeronautics and Astronautics, and Director of Heart Science and Medical Devices Research Center National Cheng Kung University Tainan         

 

 

Dr. Lu’s research in aeronautics has involved the development of method, algorithm and experiment in the areas of (1) High-resolution schemes for capturing shock waves and acoustic waves, (2) Flutter analysis in frequency and time domain concerning both internal and external aerodynamics, (3) Active acoustic flutter suppression, (4) Self-excited unsteady flow and flow control, and (5) Experimental studies on flutter and flutter suppression.

Dr. Lu has been deeply involved in the aviation safety reform of Taiwan. He started his researches on accident/incident investigation and preventive maintenance of aeroengine in 1995. The areas Dr. Lu has been working on include (1) Engine condition monitoring and fault diagnostics, (2) Flight path reconstruction, (3) Neural network-based flight loads monitoring, (4) Aviation safety reporting system, and (5) Crew/corporate resource management.

Since 1998 Dr. Lu initiated his newest research area in biomedical engineering. He organized a research team consisting of engineers, veterinarians, and cardiac surgeon, collaborating together on developing the long-term implantable ventricular assist device. In 1999, the Heart Science and Medical Devices Research Center was founded in NCKU and Dr. Lu was appointed as the Director. He now leads a team devoted in the design, in-vitro and in-vivo testing of a novel Dual-Pulsation bi-Ventricular Assist Device (DPbi-VAD). DPbi-VAD is a minimally invasive, early interventional next-generation assist device for treating heart failure. In 2009 a venture capital investment was attracted to further commercialize this new invention. A start-up company “3R Biotechnologies, Ltd.” was founded and Dr. Lu was appointed as the Chief Advisor/CEO, responsible for proving the efficacy and safety of the device as well as other administrative works.